RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone
An analysis of patient-reported outcomes from the phase 3 CANDOR trial
Weisel, K., Mateos, M.-V., Landgren, O., Leleu, X., Quach, H., Bennett, L., Talpes, M., Majer, I., Patel, S., & Usmani, S. Z. (2025). Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone: An analysis of patient-reported outcomes from the phase 3 CANDOR trial. Clinical Lymphoma, Myeloma and Leukemia. Advance online publication. https://doi.org/10.1016/j.clml.2025.02.005
BACKGROUND: In the phase 3 CANDOR trial (NCT03158688), daratumumab added to carfilzomib and dexamethasone (KdD) significantly prolonged progression-free survival relative to carfilzomib and dexamethasone (Kd) alone in previously treated patients with relapsed/refractory multiple myeloma (RRMM).
MATERIALS AND METHODS: We present a post hoc analysis of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-item module (EORTC QLQ-C30) and EORTC QLQ Myeloma 20-item module (EORTC QLQ-MY20) patient-reported outcome (PRO) measures from the CANDOR trial.
RESULTS: Median (range) duration of observation for PROs was 18.4 (0.9-50.0) months (KdD) and 10.3 (0.9-48.4) months (Kd). PRO compliance rates were high and similar between arms. Mean scores on the EORTC QLQ-C30 global health status (GHS)/quality-of-life (QOL) scale were numerically higher in the KdD than in the Kd arm and were generally sustained or trended toward improvement from baseline. Other EORTC QLQ-C30, EORTC QLQ-MY20, and EQ-5D visual analog scale (VAS) scores were generally similar between treatment arms and were stable over time, with some numerical trends favoring KdD. Risks of deterioration were similar for most scales; hazard ratios suggested improvement for KdD for EORTC QLQ-C30 social functioning, EORTC QLQ-MY20 disease symptoms, and EQ-5D VAS. Results were consistent for lenalidomide-exposed and lenalidomide-refractory subgroups. EORTC QLQ-C30 GHS/QOL scores trended toward improvement at some time points, and other scores remained generally stable when daratumumab was added to carfilzomib and dexamethasone.
CONCLUSION: These results support the benefits of KdD for the RRMM population, including lenalidomide-exposed and lenalidomide-refractory patients.